EMA grant LIfT 'ATMP Classification'

  • Published on 1st May 2017

The European Medicines Agency (EMA) have classified LIfT's enhanced allogeneic granulocyte therapy as a somatic cell therapy MP, a type of Advanced Therapeutic Medicinal Product (ATMP).

LIfT BioSciences CEO, Alex Blyth, commented that "ATMP status (rather than being a medical procedure) in an orphan disease like Pancreatic Cancer, gives LIfT BioSciences significant advantages in getting to market faster with the Early Access Scheme off a single step trial and a Market Exclusivity license. Subject of course to the planned small clinical trial showing the same kind of great results we have seen in the lab. But this is certainly an important step forward". 


We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.